ASF vaccine production no longer has to rely on live pigs and their fresh cells.
The U.S. Department of Agriculture’s Agricultural Research Service (ARS) announced May 7 that an African swine fever (ASF) vaccine candidate has been adapted to grow in a cell line, which means that those involved in vaccine production will no longer have to rely on live pigs and their fresh cells for vaccine production.
“This opens the door for large-scale vaccine production, which is a valuable tool for the possible eradication of the virus,” said senior ARS scientist Dr. Manuel Borca.
ASF is known to cause virulent, deadly outbreaks in wild and domestic swine, causing widespread and lethal outbreaks in various countries in Eastern Europe and throughout Asia. While ASF is not a threat to humans and cannot be transmitted from pigs to humans, outbreaks have led to significant economic losses and pork shortages on local and global scales.
Subscribe
New research led by Nita A. Limdi at the University of Alabama at Birmingham reports that the presence of chronic kidney disease is a major factor affecting the efficacy and safety of anticoagulant medications taken to prevent blood clots. The findings, reported in Clinical Pharmacology and Therapeutics, shine a spotlight on the effects of chronic kidney disease on the outcomes of patients taking traditional anticoagulants or newer direct-acting oral anticoagulants.
Patients with cardiovascular disease are frequently prescribed anticoagulants to prevent blood clots from forming and potentially leading to stroke or systemic embolism. The new study looked at traditional anticoagulants such as warfarin, and a newer class of direct-acting anticoagulants, such as apixaban, dabigatran and others.
ORAU will support COVID-19 communications for CDC Office of Minority Health & Health Equity
Posted at
Part of the ORAU campus in central Oak Ridge is pictured above on May 29, 2017. (File photo by John Huotari/Oak Ridge Today)
ORAU was recently awarded a contract by the Centers for Disease Control and Prevention Office of Minority Health and Health Equity (OMHHE) to provide technical communications support to the office and three COVID-19 award recipients.
ORAU will advise the development of awardee health communication plans and materials targeting limited English proficiency audiences, such as Hispanic or Asian/Pacific Islander populations, as well as help increase the communications capacity of OMHHE to respond to COVID-19 in these and other high-risk communities, a press release said.
ORAU receives new work from CDC Office of Minority Health and Health Equity to support COVID-19 communications efforts
Posted at
Oak Ridge, Tenn. ORAU recently was awarded a contract by the Centers for Disease Control and Prevention Office of Minority Health and Health Equity (OMHHE) to provide technical communications support to the office and three COVID-19 award recipients.
ORAU will advise the development of awardee health communication plans and materials targeting limited English proficiency audiences, such as Hispanic or Asian/Pacific Islander populations, as well as help increase the communications capacity of OMHHE to respond to COVID-19 in these and other high-risk communities.
The U.S. Department of Energy (DOE) Building Technologies Office (BTO) is excited to introduce the inaugural cohort of Innovation in Buildings (IBUILD) Graduate